Table 1.

Second Messenger Cyclic-GMP Activation with NPA7 or NPA7 + MasR-inhibitor A779

	Pre- Infusion	Infusion	Post-infusion
DRUG
	BL	DRUG	WO	REC1	REC2
Plasma cGMP, pmol/mL⁻¹
NPA7	9±1	119±32^*	107±33^*	77±18^†	58±13
NPA7 + A779	7±1	15±2^*§	19±3^*∥	12±1^†	9±1
Urinary cGMP excretion, pmol/mL⁻¹
NPA7	846±121	13477±1943^*	14801±2392^*	11003±2006^*	7032±1198^‡
NPA7 + A779	706±80	1783±316^†§	2039±388^†§	1646±399^‡§	1206±357^‡
Renal cGMP generation, pmol/mL⁻¹
NPA7	469±96	8233±1605^*	9630±1119^*	7612±1199^*	4677±845^‡
NPA7 + A779	453±59	1133±196^§	1269±254^‡§	1123±306^§	854±210^¶

NPA7 and NPA7 + MasR-inhibitor A779 groups were analyzed using two-way rANOVA with Bonferroni’s test for multiple comparisons. Within group differences were assessed with one-way rANOVA followed by Dunett’s test for multiple comparisons.

p<0.001 baseline (BL) change;

^†

p<0.01 BL change;

^‡

p<0.05 BL change;

^§

p<0.001 vs NPA7;

^∥

p<0.01 vs NPA7;

^¶

p<0.05 vs NPA7. BL= Baseline; DRUG= drug-infusion; WO= washout; REC1= recovery 1; REC2= recovery 2.

REC2= recovery 2 (61-90 min after DRUG).